More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$135.44B
EPS
15.53
P/E ratio
29.7
Price to sales
10.27
Dividend yield
--
Beta
0.281262
Previous close
$537.79
Today's open
$532.76
Day's range
$529 - $538.56
52 week range
$412.27 - $568.67
show more
CEO
Reshma Kewalramani
Employees
6400
Headquarters
Boston, MA
Exchange
Nasdaq Global Select
Shares outstanding
253537674
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Worried investors are paying up for these stocks — some with up to 49% upside, analysts say
Defensive sectors have beaten the S&P 500 by a wide margin in recent months, even though they are priced much higher relative to earnings estimates than the index.
Market Watch • 11 hours ago

Vertex Pharmaceuticals Eyes Nov. 30 Kidney Drug Decision as 2027 Pipeline Milestones Loom
Vertex Pharmaceuticals NASDAQ: VRTX is approaching a Nov. 30 U.S. regulatory decision for its kidney disease drug povetacicept, with a series of clinical readouts expected through 2027 as the company seeks to expand beyond its cystic fibrosis business.
MarketBeat • Nov 17, 2026

Vertex Pharmaceuticals Incorporated (VRTX) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Seeking Alpha • Nov 17, 2026

Johnson & Johnson vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?
Johnson & Johnson offers a diversified healthcare portfolio and massive scale across its MedTech and pharmaceutical segments. Vertex Pharmaceuticals maintains a dominant position in the cystic fibrosis market while expanding into high-growth gene therapies.
The Motley Fool • Nov 17, 2026

Vertex Pharmaceuticals Prepares for Key Kidney Drug Decision as Pipeline Readouts Loom
Vertex Pharmaceuticals NASDAQ: VRTX is preparing for a Nov. 30 U.S. regulatory decision on its kidney disease treatment povetacicept, while awaiting clinical results across kidney disease, chronic pain and other conditions, company executives said at a UBS investor event.
MarketBeat • Nov 16, 2026

Vertex Pharmaceuticals Incorporated (VRTX) Presents at UBS Global Biopharma Conference 2026 Transcript
Vertex Pharmaceuticals Incorporated (VRTX) Presents at UBS Global Biopharma Conference 2026 Transcript
Seeking Alpha • Nov 16, 2026

Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?
Amgen maintains a massive global footprint and a highly diversified portfolio of medicines for serious conditions. Vertex Pharmaceuticals dominates the cystic fibrosis market and is expanding into gene editing and pain management.
The Motley Fool • Nov 13, 2026

Impax Small Cap Fund Q3 2026 Portfolio Review
The portfolio outperformed the Russell 2000 Index in what was a difficult period for the small cap asset class. Financials was the largest contributing sector, almost entirely due to stock selection. Top contributors include Victory Capital and Acadian Asset Management.
Seeking Alpha • Nov 12, 2026

Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Zacks Investment Research • Nov 11, 2026

BioNTech vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?
BioNTech is aggressively pivoting its mRNA technology toward a deep pipeline of oncology treatments. Vertex Pharmaceuticals maintains high profitability and a dominant market share in cystic fibrosis therapies.
The Motley Fool • Nov 11, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Vertex Pharmaceuticals Incorporated commission-free¹. Build wealth for the long term using automated trading and transfers.